ALDX - Aldeyra Therapeutics To Request FDA Type D Meeting On NDA Of Reproxalap Resubmission By End Of Q3 2026 per SEC filing

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.